NASDAQ:AKCAAkcea Therapeutics Stock Price, Forecast & News

Akcea Therapeutics' stock was trading at $13.44 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, AKCA stock has increased by 5.1% and is now trading at $14.13. View which stocks have been most impacted by Coronavirus.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akcea Therapeutics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Akcea Therapeutics.

Akcea Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Akcea Therapeutics.

Akcea Therapeutics Inc (NASDAQ:AKCA) released its quarterly earnings data on Tuesday, May, 5th. The company reported ($0.42) EPS for the quarter, topping the Zacks' consensus estimate of ($0.45) by $0.03. The company earned $16.07 million during the quarter, compared to analyst estimates of $34.85 million. Akcea Therapeutics had a negative return on equity of 6.70% and a negative net margin of 8.59%. The company's revenue for the quarter was down 90.2% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.15 EPS. View Akcea Therapeutics' earnings history.

4 analysts have issued 1-year price objectives for Akcea Therapeutics' shares. Their forecasts range from $24.00 to $41.00. On average, they expect Akcea Therapeutics' stock price to reach $34.67 in the next twelve months. This suggests a possible upside of 145.3% from the stock's current price. View analysts' price targets for Akcea Therapeutics.

Headlines about AKCA stock have trended somewhat negative this week, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Akcea Therapeutics earned a news impact score of -1.3 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news about Akcea Therapeutics.

Some companies that are related to Akcea Therapeutics include United Therapeutics (UTHR), Reata Pharmaceuticals (RETA), Mirati Therapeutics (MRTX), Ultragenyx Pharmaceutical (RARE), Zai Lab (ZLAB), Arrowhead Pharmaceuticals (ARWR), Emergent Biosolutions (EBS), Myokardia (MYOK), Blueprint Medicines (BPMC), Nektar Therapeutics (NKTR), Biohaven Pharmaceutical (BHVN), Global Blood Therapeutics (GBT), Evotec (EVTCY), Amicus Therapeutics (FOLD) and GW Pharmaceuticals PLC- (GWPH). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Akcea Therapeutics investors own include Ionis Pharmaceuticals (IONS), Intelsat (I), Bank of America (BAC), Fossil Group (FOSL), Achaogen (AKAO), Ciena (CIEN), AMC Entertainment (AMC), Apollo Global Management (APO), Associated British Foods (ABF) and Chaarat Gold (CGH).

(AKCA) raised $125 million in an initial public offering (IPO) on Friday, July 14th 2017. The company issued 9,600,000 shares at a price of $12.00-$14.00 per share. Cowen and Company, Stifel and Wells Fargo Securities served as the underwriters for the IPO and BMO Capital Markets was co-manager.

Akcea Therapeutics trades on the NASDAQ under the ticker symbol "AKCA."

Shares of AKCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of AKCA stock can currently be purchased for approximately $14.13.

Akcea Therapeutics has a market capitalization of $1.43 billion and generates $488.54 million in revenue each year. The company earns $40.77 million in net income (profit) each year or $0.48 on an earnings per share basis. Akcea Therapeutics employs 248 workers across the globe.

The official website for Akcea Therapeutics is www.akceatx.com.

Akcea Therapeutics' mailing address is 22 BOSTON WHARF RD 9TH FLOOR, BOSTON MA, 02210. The company can be reached via phone at 617-207-0202 or via email at [email protected]